Prevention of atherosclerosis in patients living with HIV

References

• GrinspoonSCarrACardiovascular risk and body-fat abnormalities in HIV-infected adultsN Engl J Med2005352486215635112
   PubMed Web of Science ®Google Scholar
• GrinspoonSKGrunfeldCKotlerDPState of the Science Conference. Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS. Executivve summaryCirculation200811819821018566320
   PubMed Web of Science ®Google Scholar
• SteinJHKleinMABellehumeurJLUse of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunctionCirculation200110425726211457741
   PubMed Web of Science ®Google Scholar
• DressmanJKincerJMatveevSVHIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophagesJ Clin Invest200311138939712569165
   PubMed Web of Science ®Google Scholar
• HsuePYLoJCFranklinAProgression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infectionCirculation20041091603160815023877
   PubMed Web of Science ®Google Scholar
• HazenbergMDHamannDSchuitemakerHT cell depletion in HIV-1 infection: how CD4+ T cells go out of stockNat Immunol2000128528911017098
   PubMed Web of Science ®Google Scholar
• HuntPWMartinJNSinclairET cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapyJ Infect Dis20031871534154312721933
   PubMed Web of Science ®Google Scholar
• Friis-MollerNSabinCAWeberRCombination antiretroviral therapy and the risk of myocardial infarctionN Engl J Med20033491993200314627784
   PubMed Web of Science ®Google Scholar
• Friis-MollerNReissPSabinCAClass of antiretroviral drugs and the risk of myocardial infarctionN Engl J Med20073561723173517460226
   PubMed Web of Science ®Google Scholar
• VittecoqDEscautLChironiGCoronary heart disease in HIV-infected patients in the highly active antiretroviral treatment eraAIDS200317Suppl 1S70S7612870533
   PubMedGoogle Scholar
• LaRosaJCGrundySMWatersDDIntensive lipid lowering with atorvastatin in patients with stable coronary diseaseN Engl J Med20053521425143515755765
   PubMed Web of Science ®Google Scholar
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trialLancet200236072212114036
   PubMed Web of Science ®Google Scholar
• ColhounHMBetteridgeDJDurringtonPNPrimary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trialLancet200436468569615325833
   PubMed Web of Science ®Google Scholar
• GrinspoonSKGrunfeldCKotlerDPState of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summaryCirculation20081182198210Erratum in: Circulation. 2008;118(6):e109.18566320
   PubMed Web of Science ®Google Scholar
• GazzardBBernardAJBoffitoMBritish HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006)HIV Med2006748750317105508
   PubMed Web of Science ®Google Scholar
• EronJJrYeniPGatheJJrThe KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: A randomised non-inferiority trialLancet200636847648216890834
   PubMed Web of Science ®Google Scholar
• CurrierJSTaylorABoydFCoronary heart disease in HIV-infected individualsJ Acquir Immune Defic Syndr20033350651212869840
   PubMed Web of Science ®Google Scholar
• El-SadrWNeatonJEpisodic CD4-guided use of ART is inferior to continuous therapy: Results of the SMART StudyPaper presented at: Conference on Retroviruses and Opportunistic Infections (CROI)2006Denver
   Google Scholar
• KleinDHurleyLQuesenberryCHospitalizations for CHD and MI among Northern California HIV+ and HIV− men: changes in practice and Framingham Risk ScoresPaper presented at: Conference on Retroviruses and Opportunistic Infections (CROI)2006Denver
   Google Scholar
• MooreRKerulyJIncreasing Incidence of Cardiovascular Disease in HIV-infected Persons in CarePaper presented at: Conference on Retroviruses and Opportunistic Infections (CROI)2003Boston
   Google Scholar
• RickertsVBrodtHStaszewskiSIncidence of myocardial infarctions in HIV-infected patients between 1983 and 1998: the Frankfurt HIV-cohort studyEur J Med Res2000532933310958765
   PubMedGoogle Scholar
• Available at: http://www.hivforum.org/publications/CVD%20risk%20aug%2019%20w%20logo.pdf
   Google Scholar
• PignoliPTremoliEPoliAIntimal plus medial thickness of the arterial wall: A direct measurement with ultrasound imagingCirculation198674139914063536154
   PubMed Web of Science ®Google Scholar
• ChamblessLEHeissGFolsomARAssociation of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: The Atherosclerosis Risk in Communities (ARIC) Study, 1987–1993Am J Epidemiol19971464834949290509
   PubMed Web of Science ®Google Scholar
• BotsMLHoesAWKoudstaalPCommon carotid intima-media thickness and risk of stroke and myocardial infarction: The Rotterdam StudyCirculation199796143214379315528
   PubMed Web of Science ®Google Scholar
• O’LearyDHPolakJFKronmalRAfor the Cardiovascular Health Study Collaborative Research GroupCarotid-artery intima media thickness as a risk factor for myocardial infarction and stroke in older adultsN Engl J Med199934014229878640
   PubMed Web of Science ®Google Scholar
• EspelandMACravenTARileyWAReliability of longitudinal ultrasonic measurements of carotid intima-medial thicknessStroke1996274804858610317
   PubMed Web of Science ®Google Scholar
• FurbergCDAdamsHPJrApplegateWBfor the Asymptomatic Carotid Artery Progression (ACAPS) Study Research GroupEffects of lovastatin on early carotid atherosclerosis and cardiovascular eventsCirculation199490167916877734010
   PubMed Web of Science ®Google Scholar
• MaggiPSerioGEpifaniGPremature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitorsAIDS20001412312810708282
   PubMed Web of Science ®Google Scholar
• DepaironMChessexSSudrePwith the Swiss HIV Cohort StudyPremature atherosclerosis in HIV-infected individuals: focus on protease inhibitor therapyAIDS20011532933411273212
   PubMed Web of Science ®Google Scholar
• SeminariEPanAVoltiniGAssessment of atherosclerosis using carotid ultrasonography in a cohort of HIV-positive patients treated with protease inhibitorsAtherosclerosis200216243342811996964
   PubMed Web of Science ®Google Scholar
• ChironiGEscautLGariepyJCarotid intima-media thickness in heavily pretreated HIV-infected patientsJ Acquir Immune Defic Syndr20033249049312679699
   PubMedGoogle Scholar
• MerciePThiébautRLavignolleVEvaluation of cardiovascular risk factors in HIV-1 infected patients using carotid intima-media thickness measurementAnn Med200234556312014436
   PubMed Web of Science ®Google Scholar
• HowardGSharrettARHeissGCarotid artery intimal-media thickness distribution in general populations as evaluated by B-mode ultrasoundStroke199324129713048362421
   PubMed Web of Science ®Google Scholar
• AminbakhshAManciniGBJCarotid intima-media thickness measurements: what defines an abnormality? A systematic reviewClin Invest Med19992214915710497713
   PubMed Web of Science ®Google Scholar
• CharakidaMDonaldAEGreenHEarly structural and functional changes of the vasculature in HIV-infected children: impact of disease and antiretroviral therapyCirculation200511210310915983247
   PubMed Web of Science ®Google Scholar
• YuCMZhangQLamLComparison of intensive and low-dose atorvastatin therapy in the reduction of carotid intimal-medial thickness in patients with coronary heart diseaseHeart20079393393917344325
   PubMed Web of Science ®Google Scholar
• CrouseJR3rdRaichlenJSRileyWAEffect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR TrialJAMA20072971344135317384434
   PubMed Web of Science ®Google Scholar
• BaigentCKeechAKearneyPMEfficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statinsLancet20053661267127816214597
   PubMed Web of Science ®Google Scholar
• CrouseJR3rdThematic review series: patient-oriented research. Imaging atherosclerosis: state of the artJ Lipid Res2006471677169916705212
   PubMed Web of Science ®Google Scholar
• NissenSENichollsSJSipahiIEffect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trialJAMA20062951556156516533939
   PubMed Web of Science ®Google Scholar
• Rodriguez-GranilloGAAgostoniPGarcia-GarciaHMMeta-analysis of the studies assessing temporal changes in coronary plaque volume using intravascular ultrasoundAm J Cardiol20079951017196453
   PubMed Web of Science ®Google Scholar
• de GrootEJukemaJWMontauban van SwijndregtADB-mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings: a report of the Regression Growth Evaluation Statin Study (REGRESS)J Am Coll Cardiol199831156115679626835
   PubMed Web of Science ®Google Scholar
• SalonenRNyyssonenKPorkkalaEKuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteriesCirculation199592175817647671358
   PubMed Web of Science ®Google Scholar
• AmarencoPLabreucheJLavalleePStatins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysisStroke2004352902290915514180
   PubMed Web of Science ®Google Scholar
• JonesPHDavidsonMHSteinEAComparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial)Am J Cardiol20039215216012860216
   PubMed Web of Science ®Google Scholar
• SchusterHBarterPJStenderSEffects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) studyAm Heart J200414770571315077101
   PubMed Web of Science ®Google Scholar
• JonesPHHunninghakeDBFerdinandKCEffects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trialClin Ther2004261388139915531001
   PubMed Web of Science ®Google Scholar
• LibbyPRidkerPMInflammation and atherosclerosis: role of C-reactive protein in risk assessmentAm J Med2004116Suppl 6A9S16S15050187
   PubMed Web of Science ®Google Scholar
• RidkerPMHigh-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular diseaseCirculation20011031813181811282915
   PubMed Web of Science ®Google Scholar
• JialalIDevarajSThe role of C-reactive protein activation of nuclear factor kappa-B in the pathogenesis of unstable anginaJ Am Coll Cardiol20074919519717222730
   PubMedGoogle Scholar
• HsuePLoJFranklinAC-reactive protein levels in patients with HIV: a marker of cardiovascular risk or chronic infection?Paper presented at: Conference on Retroviruses and Opportunistic Infections (CROI)2005Boston
   Google Scholar
• HenryKZackinRDubeMACTG 5056: C-Reactive protein (CRP) levels and cardiovascular risk status for a cohort of HIV-1-infected persons Durably suppressed on an indinavir (IDV)-containing regimenPaper presented at: Conference on Retroviruses and Opportunistic Infections (CROI)2002Seattle
   Google Scholar
• NoursadeghiMMillerRFClinical value of C-reactive protein measurements in HIV-positive patientsInt J STD AIDS20051643844115969780
   PubMedGoogle Scholar
• FeldmanJGGoldwasserPHolmanSC-reactive protein is an independent predictor of mortality in women with HIV-1 infectionJ Acquir Immune Defic Syndr20033221021412571532
   PubMed Web of Science ®Google Scholar
• LauBSharrettARKingsleyLAC-reactive protein is a marker for human immunodeficiency virus disease progressionArch Intern Med2006166647016401812
   PubMed Web of Science ®Google Scholar
• de LorenzoFFeherMMartinJStatin therapy-evidence beyond lipid lowering contributing to plaque stabilityCurr Med Chem2006133385339317168712
   PubMedGoogle Scholar
• JainMKRidkerPMAnti-inflammatory effects of statins: clinical evidence and basic mechanismsNat Rev Drug Discov2005497798716341063
   PubMed Web of Science ®Google Scholar
• RidkerPMCannonCPMorrowDC-reactive protein levels and outcomes after statin therapyN Engl J Med2005352202815635109
   PubMed Web of Science ®Google Scholar
• RidkerPMWilsonPWGrundySMShould C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?Circulation20041092818282515197153
   PubMed Web of Science ®Google Scholar
• MassyZAKeaneWFKasiskeBLInhibition of the mevalonate pathway: benefits beyond cholesterol reduction?Lancet19963471021038538301
   PubMed Web of Science ®Google Scholar
• SpositoACChapmanMJStatin therapy in acute coronary syndromes: mechanistic insight into clinical benefitArterioscler Thromb Vasc Biol2002221524153412377727
   PubMed Web of Science ®Google Scholar
• LiaoJKIsoprenoids as mediators of the biological effects of statinsJ Clin Invest200211028528812163444
   PubMed Web of Science ®Google Scholar
• SmithDAGalinIStatin therapy for native and peri-interventional coronary heart diseaseCurr Mol Med2006658960216918378
   PubMedGoogle Scholar
• HaydenMSGhoshSSignaling to NF-kappa BGenes Dev2004182195222415371334
   PubMed Web of Science ®Google Scholar
• WongBLummaWCSmithAMStatins suppress THP-1 cell migration and secretion of matrix metalloproteinase 9 by inhibiting geranylgeranylationJ Leukoc Biol2001699596211404382
   PubMed Web of Science ®Google Scholar
• FeinbergMWLinZFischSAn emerging role for Kruppel-like factors in vascular biologyTrends Cardiovasc Med20041424124615451516
   PubMed Web of Science ®Google Scholar
• PlutzkyJPeroxisome proliferator-activated receptors as therapeutic targets in inflammationJ Am Coll Cardiol2003421764176614642685
   PubMed Web of Science ®Google Scholar
• LinZKumarASenBanerjeeSKruppel-like factor 2 (KLF2) regulates endothelial thrombotic functionCirc Res200596e48e5715718498
   PubMed Web of Science ®Google Scholar
• SenBanerjeeSLinZAtkinsGBKLF2 Is a novel transcriptional regulator of endothelial proinflammatory activationJ Exp Med20041991305131515136591
   PubMed Web of Science ®Google Scholar
• ParmarKMNambudiriVDaiGStatins exert endothelial atheroprotective effects via the KLF2 transcription factorJ Biol Chem2005280267142671915878865
   PubMed Web of Science ®Google Scholar
• LandrierJFThomasCGroberJStatin induction of liver fatty acid-binding protein (L-FABP) gene expression is peroxisome proliferator-activated receptor-alpha-dependentJ Biol Chem2004279455124551815337740
   PubMedGoogle Scholar
• ZelvyteIDominaitieneRCrisbyMModulation of inflammatory mediators and PPARgamma and NFkappa B expression by pravastatin in response to lipoproteins in human monocytes in vitroPharmacol Res20024514715411846628
   PubMed Web of Science ®Google Scholar
• JBS 2: Joint British Societies’ guidelines on the prevention of cardiovascular disease in clinical practiceHeart200591Suppl 5v1v5216365341
   PubMedGoogle Scholar
• Van Der LeeMVogelMSchippersEPharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patientsPaper presented at: Conference on Retroviruses and Opportunistic Infections (CROI)2006Denver
   Google Scholar
• KiserJJGerberJGPredhommeJADrug/drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteersJ Acquir Immune Defic Syndr20084757057818176327
   PubMed Web of Science ®Google Scholar
• SmithJMuch about HIVBMJ200733417303861
   PubMedGoogle Scholar
• TaylorAJKentSMFlahertyAJARBITER: Arterial biology for the investigation of the treatment effects of reducing cholesterol: A randomized trial comparing the effects of aforvastatin and pravastatin on carotid intima media thicknessCirculation20021062055206012379573
   PubMed Web of Science ®Google Scholar
• SmildeTJWollersheimHvan LangenHReproducibility of ultrasonographic measurements of different carotid and femoral artery segments in healthy subjects and in patients with increase intima-media thicknessClin Sci (Lond)1997933173249404223
   PubMed Web of Science ®Google Scholar
• MarkwoodTTKentsSCoyleLCDesign and rationale of the ARBITER trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol) – a randomized trial comparing the effects of atorvastatin and pravastatin on carotid artery intima-media thicknessAm Heart J200114134234711231429
   PubMedGoogle Scholar
• RidkerPMRifaiNPfefferMALong-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) InvestigatorsCirulcation1999100230235
   PubMed Web of Science ®Google Scholar